Christopher Baum, MD
Title
Adjunct Associate Professor
Appointment
Adjunct Associate Professor, University of Cincinnati College of Medicine
Email
christopher.baum@cchmc.org
Phone
513-636-1333
Fax
513-636-1330
Bio
Christopher Baum, MD was born April 13, 1962 in Marburg, Germany. He studied philosophy and medicine in Freiburg and Hamburg, Germany. He received his certification and MD in 1991. In 1992, Baum pursued postgraduate training in molecular biology at the University of Hamburg; his focus was the expression analysis of novel Nkx homeobox genes. Since 1996, he has led the research group in retroviral vector development for genetic modification of hematopoietic cells at Heinrich-Pette-Institut in Hamburg. In 2000, Baum moved his lab to Hannover Medical School (Germany), one of the largests centers for organ transplantation in Europe. Since April 2006 Dr. Baum is Full Professor and Head of the Deparmtent of Experimental Hematology at the Hannover Medical School. He works as an Adjunct Associate Profesor in Cincinnati Children's Hospital since July 2002.
Credentials
MD: University of Hamburg, Germany, 1991.
Habilitation in Molecular Medicine: University of Hamburg, Germany, 1999.
Associate Professor for Stem Cell Biology: Hannover Medical School, Hannover, Germany, 2000.
Full Professor, Head of Department of Experimental Hematology: Hannover Medical School, Hannover, Germany, 2006.
Adjunct Associate Professor of Pediatrics, Molecular and Gene Therapy Program: Cincinnati Children's Research Foundation; University of Cincinnati, OH, 2002.
Awards and Honors
- President, German Society of Gene Therapy, 2006.
- Langen Award, 2005 (together with Christof von Kalle, Manfred Schmidt and Boris Fehse).
- Sir Hans Krebs Awards, 2005 (together with co-authors of Kustikova et al., Science 2005).
- Elected member, American Society for Clinical Investigation, 2003.
- Konietzny Publication Award, Hamburg Cancer Society, 2002.
- Young Scientists Travel Award, American Society of Gene Therapy, 1998
- Farmitalia Carlo-Erba Award "Pathogenesis, pathophysiology and therapy of malignant tumors", 1995
- Joseph-Kimmig Graduate Student Research Award, 1988 (for the thesis)
Research
Connect to Christopher Baum's Laboratory webpageResearch Grants and Contracts
Grants from the European Union, German Research Foundation, German Ministery for Research and Education; PI in all grants. R01 grant from the NCI in the US.
Publications, Most Recent
Connect to Christopher Baum's publications on PubMed
Modlich U, Bohne J, Schmidt M, von Kalle C, Knob S, Schambach A, Baum C. Novel Cell culture assays reveal the importance of retroviral vector design for insertionals genotoxicity.Blood 2006; July 6 [epub ahead of print]
Schambach A, Juller D, Galla M, Baum C, Bohne J. Overcoming promoter interference in packaging cells improves producation of self-inactivating retroviral vectors.Gene Therapy 2006; June 8 [epub ahead of print]
Schambach, A, Schiedlmeier B, Kuhicke K, Verstegen M, Margison G, Li Z, Kamino K, Bahne J, Alexandrov A, Hermann FG, von Laer D, Baum C. Towards hematopoietic stem cell-mediated protection against infection with human immunodeficiency virus.Gene Therapy 2006; 13:1037-1047.
Schambach A, Galla M, Modlich U, Will E, Chandra S, Reeves L, Colbert M, Williams DA, von Kalle C, Baum C. Lentiviral vectors pseudotyped with murine ecotropic evelope: Increased biosafety and convenience for preclinical research.Experimental Hematology 2006; 34-588-592.
Schambach A, Bohne J, Baum C, Hermann FG, Egerer L, von Laer D, Giroglou T. Woodchuck hepatitis virus posttranscriptional regulatory element deleted from X protein enhances retroviral vector titer and expression.Gene Therapy 2006; 13:241-246.
Schambach A, Bohne J, Chandra S, Will E, Margison G, Williams DA, Baum C. Equal potency of gammaretroviral and lentiviral SIN vectors for expression of O6-methylguanine-DNA-methyltransferase in bone marrow cells.Mol Ther. 2006; 13; 391-400.
Pilat S, Carotta S, Schiedlmeier B, Kamino K, Meirhofer A, Will E, Modlich U, Ostertag W, Steinlein P, Baum C, Beug H, Klump H. HOXB4 enforces equivalent fates of ES-Cell derived and adult hematopoietic cells.Proc Natl Acad Sci U S A. 2005 Aug 23;102(34):12101-6.
Kustikova O, Fehse B, Modlich U, Düllmann J, Kamino K, von Neuhoff N, Schlegelberger B, Li Z, Baum C. Clonal dominance of hematopoietic stem cells triggered by retroviral gene marking.Science. 2005 May 20;308(5725):1171-4.
Beutel G, Meyer J, Ma L, Yin S, Eder M, von Neuhoff N, Wilkens L, Wei J, Hertenstein B, Heil G, Schlegelberger B, Ganser A, Li Z, Baum C. Expression of the p75 neurotrophin receptor in acute leukemia.British Journal of Haematology 2005; 131:67-70.
Lorico A, Bratbak D, Meyer J, Kunke D, Krauss S, Plott WE, Solodushko V, Baum C, Fodstad O, Rappa G. ?-Glutamyl cysteine synthetase and L-buthionine-S, R. sulfoximinie (BSA): a new selction strategy for gene-transduced neural and hematopoietic stem/progenitor cells.Human Gene Therapy 2005; 16:711-724.
Modlich U, Kustikova O, Schmidt M, Rudolph C, Meyer J, Li Z, Kamino K, von Neuhoff N, Schlegelberger B, Kuehlcke K, Bunting KD, Schmidt S, Deichmann A, von Kalle C, Fehse B, Baum C. Leukemias following retroviral transfer of multidrug resistance 1 are driven by combinatorial insertional mutagenesis.Blood. 2005 Jun 1;105(11):4235-46.
Galla M, Will E, Kraunus J, Chen L, Baum C. Retroviral pseudotransduction for targeted cell manipulation.Mol Cell. 2004 Oct 22;16(2):309-15.
Frank O, Rudolph C, Heberlein C, von Neuhoff N, Schröck E, Schambach A, Schlegelberger B, Fehse B, Schambach A, Ostertag W, Stocking C, Baum C. Tumor cells escape suicide gene therapy by genetic and epigenetic instability.Blood. 2004 Dec 1;104(12):3543-9.
Loew R, Selevsek N, Fehse B, von Laer D, Baum C, Fauser A, Kuehicke K. Simplified generation of high-titer retrovirus producer cells for clinically relevant retroviral vectors by reversible inclusion of loxP-flanked marker gene.Molecular Therapy 2004; 9:738-746.
Kraunus J, Schaumann DHS, Meyer J, Modlich U, Fehse B, Brandenburg G, von Laer D, Klump H, Baum C. Self-inactivating retroviral vectors with improved RNA processing.Gene Ther. 2004 Nov;11(21):1568-78.
Werner M, Kraunus J, Baum C, Brocker T. B cell-specific transgene expression using a self-inactivating retroviral vector with human CD19 promoter and viral posttranscriptional regulatory fibronectin.Gene Therapy 2004; 11:992-1000.
Rappa G, Kunke D, Holter J, Diep DB, Meyer J, Baum C, Folstad O, Krauss S, Lorico A. Efficient expansion and gene transduction of mouse neural stem/progenitor cells on recombinant fibronectin.Neuroscience 2004; 124:823-830.
Egelhofer M, Brandenburg G, Martinius H, Schult-Dietrich P, Melikyan G, Kunert R, Baum C, Choi I, Alexandrov A, von Laer D. Inhibition of HIV-1 entry in cells expressing Gp41-derived peptides. Journal of Virology 2004; 78:568-575.
Yamaguchi K, Itoh K, Ohnishi N, Ito Y, Baum C, Tsuji T, Nagao T, Higashitsuji H, Okanoue T, Fujita J. Engineered long terminal repeats of retroviral vectors enhance transgene expression in hepatocytes in vitro and in vivo.Molecular Therapy 2003; 8:796-803.
Kustikova O, Wahlers A, Kuehcke K, Staehle B, Zander AR, Baum C, Fehse B. Dose finding with retroviral vectors: Correlation of retroviral vector copy numbers in single cells with gene transfer efficiency in a cell population.Blood. 2003 Dec 1;102(12):3934-7.
Li Z, Schwieger M, Lane C, Kraunus J, Sun H, von den Akker E, Modlich U, Serinosoz E, Will E, von Laer D, Stocking C, Fehse B, Schiedlmeier B, Baum C. Predictable and efficient retroviral gene transfer into murine bone marrow repopulating cells using a defined vector dose. Experimental Hematology 2003; 31:1206-1214.
Engels B, Cam H, Schuler T, Indraccolo S, Gladow M, Baum C, Blankenstein T, Uckert W. Retroviral vectors for high transgene expression in T lymphocytes. Human Gene Therapy 2003; 14:1155-1168.
Schiedlmeier B, Klump H, Will E, Arman-Kalcek G, Li Z, Wang Z, Rimek A, Friel J, Baum C, Ostertag W. High level ectopic HOXB4 expression confers a profound in vivo competitive growth advantage to human cord blood CD34+ cells, but impairs lymphomyeloid differentiation.Blood. 2003 Mar 1;101(5):1759-68.
Rappa G Gamszik MP, Mitina RL, Baum C, Faodstad O, Lorico A. Retroviral transfer of MRP1 and gamma-glutamyl cysteine synthetase modulates cell sensitivity to L-buthionine-S,R-sulphoximine (BSO): new rationale for the use of BSO in cancer therapy. Euripean Journal of Cancer 2003;39:120-128.
Cmejlova J, Hildinger M, Cmejla R, fuchs O, Zakova D, Baum C, Jelinek J. Impact of splice-site mutations of the MDR1 cDNA on stability and expression of retroviral vectors. Gene Therapy 2003; 10:1061-1065.
Peer-reviewed Review Articles
Baum C, Kustikova O, Modlich U, Li Z, Fehse F. Mutagenesis and oncogenesis by chromosomal insertion of transgene vectors.Human Gene Therapy 2006; 17:253-263.
Baum C, Schambach A, Bahne J, Galla M. Retrovirus vectors: Toward the plentivirus.Molecular Therapy 2006, epub 21 April 2006.
von Kalle C, Fehse B, Leyh-Schmidt G, Schmidt M, Kelly P, Baum C. Stem cell clonality and genotoxicity in hematopoietic cells: gene activation side effects should be avoidable.Seminars in Hematology 2004; 4:303-318.
von Kalle C, Baum C, Williams DA. Lenti in red: progress in molecular therapy for human hemoglobinopathies.J Clin Invest. 2004;114 :889-891.
Fehse B, Kustikova O, Bubenheim M, Baum C. Pois(s)on – It's a question of dose…Gene Therapy 2004; 11:879-881.
Klein C, Baum C. Gene therapy for inherited disorders of haematopoietic cells.The Hematology Journal 2004; 5:103-111.
Baum C, von Kalle C, Stall FJT, Li Z, Fehse B, Schmidt M, Weerkamp F, Karlsson S, Wagemaker S, Williams D. Chance or necessity? Insertional mutagenesis in gene therapy and its consequences.Molecular Therapy 2004; 9:5-13.
Williams DA, Baum C. Medicine: Gene Therapy – New Challenges ahead.Science 2003; 302:400-401.
Baum C, Fehse B. Mutagenesis by retroviral transgene insertion: Risk assessment and potential alternatives.Current Opinion in Molecular Therapeutics 2003; 5:458-462.
Baum C, Düllmann J, Li Z, Fehse B, Meyer J, Williams DA, von Kalle C. Side effects of retroviral gene transfer into hematopoietic stem cells.Blood 2003; 101:2099-2114.
Editorial Positions
- Gene Therapy (Editorial Board since 2004)
- Molecular Therapy (Editorial Board since 2004)
- Human Gene Therapy (Editorial Board since 2005)
Professional Organization Memberships
- American Society for Clinical Investigation, 2003
- International Society of Experimental Hematology, 2001
- American Society of Hematology, 2000
- American Society of Gene Therapy, 2000
- European Society of Gene Therapy, 1999 (Member of vector committee since 2003)
- German Society of Gene Therapy, 1998 (President since 2006)
Special Interests
Retrovirus biology and vectorology, Stem cell biology, Gene therapy, Leukemia biology
Related Areas
This person works in these other areas at Cincinnati Children's Hospital Medical
Center:
